This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scher, H. I. Articles by Sawyers, C. L. Search for Related Content PubMed PubMed Citation Articles by Scher, H. I. Articles by Sawyers, C. L.

Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis

Howard I. Scher, Charles L. Sawyers

From the Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center; Joan and Sanford E. Weill College of Medicine of Cornell University, New York, NY; Howard Hughes Medical Institute, University of California, Los Angeles/Hematology-Oncology, Los Angeles, CA

Address reprint requests to Howard I. Scher, MD, Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center1275 York Ave, New York, NY 10021; e-mail: Scherh{at}mskcc.org.

Prostate cancers that are progressing on medical and surgical therapies designed to ablate the action of androgens continue to express androgen receptor (AR) and to depend on signaling through the receptor for growth. A more clinically relevant classification of castration-resistant disease focuses on the mechanisms of receptor activation, which include (1) changes in the level of ligand(s) in tumor tissue; (2) increased levels of the protein due to gene amplification or altered mRNA expression; (3) activating mutations in the receptor that affect structure and function; (4) changes in coregulatory molecules including coactivators and corepressors; and (5) factors that lead to activation of the receptor independent of the level of ligand or receptor allowing kinase cross talk. From an AR perspective, the term "hormone refractory" is inappropriate. On the basis of this schema, we discuss strategies that are focused on the AR either directly or indirectly, as single agents or in combination, that are in clinical development.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				L. A. Ponguta, C. W. Gregory, F. S. French, and E. M. Wilson Site-specific Androgen Receptor Serine Phosphorylation Linked to Epidermal Growth Factor-dependent Growth of Castration-recurrent Prostate Cancer J. Biol. Chem., July 25, 2008; 283(30): 20989 - 21001. [Abstract] [Full Text] [PDF]

				K. A. Link, S. Balasubramaniam, A. Sharma, C. E.S. Comstock, S. Godoy-Tundidor, N. Powers, K. H. Cao, A. Haelens, F. Claessens, M. P. Revelo, et al. Targeting the BAF57 SWI/SNF Subunit in Prostate Cancer: A Novel Platform to Control Androgen Receptor Activity Cancer Res., June 15, 2008; 68(12): 4551 - 4558. [Abstract] [Full Text] [PDF]

				N. J. Maitland and A. T. Collins Prostate Cancer Stem Cells: A New Target for Therapy J. Clin. Oncol., June 10, 2008; 26(17): 2862 - 2870. [Abstract] [Full Text] [PDF]

				D. E. Frigo and D. P. McDonnell Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation Mol. Cancer Ther., March 1, 2008; 7(3): 659 - 669. [Abstract] [Full Text] [PDF]

				T. Hara, H. Miyazaki, A. Lee, C. P. Tran, and R. E. Reiter Androgen Receptor and Invasion in Prostate Cancer Cancer Res., February 15, 2008; 68(4): 1128 - 1135. [Abstract] [Full Text] [PDF]

				S. M. Dehm and D. J. Tindall Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer Mol. Endocrinol., December 1, 2007; 21(12): 2855 - 2863. [Abstract] [Full Text] [PDF]

				D. C. Danila, G. Heller, G. A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka, H. Lilja, L. Schwartz, S. Larson, M. Fleisher, et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7053 - 7058. [Abstract] [Full Text] [PDF]

				E. Estebanez-Perpina, L. A. Arnold, P. Nguyen, E. D. Rodrigues, E. Mar, R. Bateman, P. Pallai, K. M. Shokat, J. D. Baxter, R. K. Guy, et al. A surface on the androgen receptor that allosterically regulates coactivator binding PNAS, October 9, 2007; 104(41): 16074 - 16079. [Abstract] [Full Text] [PDF]

				W. Kleeberger, G. S. Bova, M. E. Nielsen, M. Herawi, A.-Y. Chuang, J. I. Epstein, and D. M. Berman Roles for the Stem Cell Associated Intermediate Filament Nestin in Prostate Cancer Migration and Metastasis Cancer Res., October 1, 2007; 67(19): 9199 - 9206. [Abstract] [Full Text] [PDF]

				M. C. Hodgson, I. Astapova, A. N. Hollenberg, and S. P. Balk Activity of Androgen Receptor Antagonist Bicalutamide in Prostate Cancer Cells Is Independent of NCoR and SMRT Corepressors Cancer Res., September 1, 2007; 67(17): 8388 - 8395. [Abstract] [Full Text] [PDF]

				N. Sharifi, E. Hamel, M. A. Lill, P. Risbood, C. T. Kane Jr., M. T. Hossain, A. Jones, J. T. Dalton, and W. L. Farrar A bifunctional colchicinoid that binds to the androgen receptor Mol. Cancer Ther., August 1, 2007; 6(8): 2328 - 2336. [Abstract] [Full Text] [PDF]

				N. G. Nickols and P. B. Dervan Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide PNAS, June 19, 2007; 104(25): 10418 - 10423. [Abstract] [Full Text] [PDF]

				B. Li, A. Sun, H. Youn, Y. Hong, P. F. Terranova, J.B. Thrasher, P. Xu, and D. Spencer Conditional Akt activation promotes androgen-independent progression of prostate cancer Carcinogenesis, March 1, 2007; 28(3): 572 - 583. [Abstract] [Full Text] [PDF]

				R. A. Miksad, G. Bubley, P. Church, M. Sanda, N. Rofsky, I. Kaplan, and A. Cooper Prostate Cancer in a Transgender Woman 41 Years After Initiation of Feminization. JAMA, November 15, 2006; 296(19): 2316 - 2317. [Full Text] [PDF]

				S. J. Desai, A.-H. Ma, C. G. Tepper, H.-W. Chen, and H.-J. Kung Inappropriate Activation of the Androgen Receptor by Nonsteroids: Involvement of the Src Kinase Pathway and Its Therapeutic Implications Cancer Res., November 1, 2006; 66(21): 10449 - 10459. [Abstract] [Full Text] [PDF]

				W. Xu, L. Ngo, G. Perez, M. Dokmanovic, and P. A. Marks Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor PNAS, October 17, 2006; 103(42): 15540 - 15545. [Abstract] [Full Text] [PDF]

				R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]

				K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]

				E. J. Small and E. A. Klein Challenges and Future Directions in the Prevention and Management of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145. [Full Text] [PDF]